Using Systems Biology to Beat Cancer | GenomeWeb

Merrimack Pharmaceuticals CEO Robert Mulroy says the traditional approach to cancer — making drugs that go after certain proteins — is "fundamentally flawed," according to the Forbes' Treatments blog's Robert Langreth. Merrimack is now working with Sanofi-Aventis to develop cancer drugs using the principles of systems biology.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

Related Posts

For Truth

Cancer Trial Halted

To Spot it Early

And, Poof, It's Gone

Anxious Allele

In PNAS this week: mutations linked to nasopharyngeal carcinoma, salivary proteins common among oral squamous cell carcinoma patients, and more.

At Wired, a science journalist discusses her decision not to undergo BRCA testing.

The Japan Times says regulations are needed to oversee human genome-editing research.

In PLOS this week: molecular surveillance of S. Typhi, genome-wide association study of attention in children, and more.